Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
The protein tyrosine phosphatase SHP2 is a key regulator of cell cycle control. Here the authors combine NMR measurements and X-ray crystallography and show that wild-type SHP2 dynamically exchanges between a closed inactive conformation and an open activated form and that the oncogenic E76K mutatio...
Guardado en:
Autores principales: | Ricardo A. P. Pádua, Yizhi Sun, Ingrid Marko, Warintra Pitsawong, John B. Stiller, Renee Otten, Dorothee Kern |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/77cc04b8724e47ce9663728a803fea11 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
por: Jonathan R. LaRochelle, et al.
Publicado: (2018) -
Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state
por: Paolo Calligari, et al.
Publicado: (2021) -
Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway.
por: Farah Ketroussi, et al.
Publicado: (2011) -
Protein tyrosine phosphatase Shp2 deficiency in podocytes attenuates lipopolysaccharide-induced proteinuria
por: Ming-Fo Hsu, et al.
Publicado: (2017) -
PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment
por: Tomohiro Takehara, et al.
Publicado: (2021)